

PRESS RELEASE

Biocon Biologics Features in the Prestigious ASIA IP ELITE List for 2022

Bengaluru, Karnataka, India, November 11, 2022

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that the Company has been featured on the prestigious Asia IP ELITE list for 2022 by Intellectual Asset Management (IAM) for its world class Intellectual Property (IP) management and IP value creation in the Asia-Pacific region.

Biocon was the first and only pharmaceutical company from India to be featured on the ASIA IP ELITE list in 2016. Biocon Biologics debuted on the list in 2019. This is the fifth consecutive year that a Biocon Group company has made it to the Asia IP ELITE list, which recognizes companies across the Asia-Pacific region that demonstrate a sustained commitment to building best-in-class in-house IP functions and continuous excellence in IP value creation.

Shreehas Tambe, Deputy Chief Executive Officer, Biocon Biologics, said: *“We are delighted that Biocon Biologics has been featured on the Asia IP ELITE 2022 list. This recognition is an endorsement of the Biocon Group’s commitment towards innovation and value creation for its stakeholders. Biocon and its subsidiaries have a strong track record of generating IP with over 1,000 granted patents for biologics till date.”*

Biocon Biologics is leveraging its robust in-house Intellectual Property (IP) strategy and capabilities to enable early entry of biosimilar products to meet patient needs in global markets

Biocon Biologics’ IP team, was honoured at the latest edition of the IP Business Congress Asia, which is hosted by Intellectual Asset Management (IAM), the publishers of the world’s leading IP magazine IAM.

A record 80 organisations around the Asia-Pacific region featured in this year’s event, which was organized after a gap of two years.

“Biocon Biologics is a prime example of an Indian life sciences company that is built on R&D and innovation, even if much of its focus is based around challenging the

entrenched patent positions of brand-name drug companies,” the IAM Special Report said.

“Most recently, the organisation’s biosimilars business has made it a central player in some of the most consequential global patent disputes in the cutting-edge biologics area. Along with [its] partner Viatrix, Biocon Biologics won landmark U.S. Food and Drug Administration interchangeability approval for its biosimilar insulin [glargine] product, following extensive patent litigation with Sanofi,” the report added.

About Biocon Biologics Ltd.

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology and other non-communicable diseases. Seven molecules from Biocon Biologics’ portfolio have been commercialized in key emerging markets and developed markets like U.S., EU, Australia, Canada, Japan. It has many firsts to its credit including the most recent U.S. FDA approval of the world’s first interchangeable biosimilar, awarded to its Insulin Glargine, which has been commercialized in the U.S. in 2021. Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to lifesaving vaccines and biologics globally. With a team of over 5,000 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. *Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics for company updates.*

About Biocon Limited

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. *Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.*

CONTACTS:	
MEDIA	
Seema Ahuja Sr VP & Global Head of Communications & Corporate Brand, Biocon Biologics & Biocon Group +91 99723 17792 seema.ahuja@biocon.com	Savya Shankar Assistant Manager, Biocon Group +91 80502 24638 savya.shankar@biocon.com